safety and efficacy of single agent rovalpituzumab tesirine in small cell lung cancer (sclc)
Published 7 years ago • 307 plays • Length 7:14Download video MP4
Download video MP3
Similar videos
-
1:31
dr. bauer on rovalpituzumab tesirine in patients with sclc
-
1:56
rovalpituzumab in small cell lung cancer (sclc)
-
4:44
catherine pietanza: safety, activity and response durability of rovalpituzumab tesirine in sclc
-
1:51
dr. bauer on rovalpituzumab tesirine in sclc
-
0:58
no clear evidence for benefit with addition of rova-t to chemo for extensive sclc
-
4:45
rova-t: first ‘targeted’ treatment for small cell lung cancer shows promise
-
2:13
trinity: rova-t for relapsed sclc
-
1:02
evaluating the role of systemic therapies in sclc
-
4:43
first in-human trials of rovalpituzumab for sclc
-
4:58
rova-t shows promise in small cell lung cancer
-
5:34
new data in sclc including the convert and rovalpituzumab
-
37:43
selective inhibition of oncogenic transcription and other approaches in the treatment of sclc
-
3:26
small cell lung cancer and immuno-oncology | what patients need to know
-
1:24
dr. pietanza on rova-t for small-cell lung cancer
-
1:16
the importance of the phase iii javelin lung 100 trial in non-small-cell lung cancer
-
3:28
the future of nsclc treatment
-
1:44
pd-l1 testing in first-line treatment of nsclc
-
0:53
future treatment options for squamous cell lung cancer
-
41:11
optimizing treatment selection, sequencing, and tolerability in small cell lung cancer